What Is the BPC-157 + TB-500 Co-Formulation?

The BPC-157 + TB-500 Co-Formulation is a dual-peptide research formulation combining BPC-157 (Body Protection Compound-157; CAS 137525-51-0) and TB-500 (Thymosin Beta-4; CAS 77591-33-4). The two compounds address distinct but mechanistically complementary aspects of tissue repair biology: BPC-157 operates primarily through modulation of growth factor receptor signaling, angiogenesis promotion, and cytoprotective pathways, while TB-500 acts via thymosin-β4-mediated actin cytoskeletal dynamics, cell migration facilitation, and extracellular matrix remodeling. Research interest in combining these compounds stems from the hypothesis that their non-overlapping mechanisms may produce additive or synergistic effects on tissue repair processes in research model systems. Both compounds are used exclusively for laboratory research purposes by qualified professionals.

Stack Composition

BPC-157: Research Profile

BPC-157 (CAS 137525-51-0; MW 1419.55 g/mol; formula C₆₂H₉₈N₁₆O₂₂) is a 15-amino acid synthetic peptide derived from a region of the gastric juice protein BPC (Body Protection Compound). Its sequence—GEPPPGKPADDAGLV—was identified through bioactivity-guided fractionation of gastric juice proteins and has been extensively studied in preclinical research models for its tissue-protective and repair-promoting properties. BPC-157 does not correspond to any characterized receptor-ligand pair in the canonical sense; instead, research has identified multiple downstream signaling effects including upregulation of VEGF (vascular endothelial growth factor), EGF receptor (EGFR), and FAK (focal adhesion kinase)-paxillin pathway activity, as well as modulation of nitric oxide (NO) synthesis. These effects converge on enhanced vascularization, fibroblast activation, and accelerated granulation tissue formation in research injury models. BPC-157 has been studied across a wide range of tissue types including tendon, ligament, skeletal muscle, bone, gastrointestinal mucosa, and peripheral nerve in preclinical research settings.

TB-500: Research Profile

TB-500 (CAS 77591-33-4; MW 4963.4 g/mol; formula C₂₁₅H₃₅₅N₅₆O₇₈S) is a synthetic 43-amino acid peptide corresponding to the full sequence of thymosin beta-4 (Tβ4), the protein encoded by the TMSB4X gene. Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian cells and functions as the primary actin G-monomer sequestering protein in non-muscle cells. By binding G-actin with high affinity, TB-500 regulates the pool of actin available for filament polymerization, thereby controlling cytoskeletal dynamics that govern cell morphology, motility, and division. In research models, the biologically active region of thymosin-β4 has been localized to the central LKKTETQ heptapeptide actin-binding motif (residues 17–23), while the N-terminal Ac-SDKP tetrapeptide exerts distinct anti-inflammatory and anti-fibrotic effects via inhibition of prolyl oligopeptidase and modulation of macrophage activation. Research investigating TB-500 has documented effects on wound closure kinetics, angiogenesis, cardiac tissue recovery following ischemia models, skeletal muscle regeneration, and corneal healing in preclinical experimental systems.

Research Rationale

The mechanistic basis for combining BPC-157 and TB-500 in research rests on the complementarity of their molecular targets and cellular actions. BPC-157 exerts its tissue-protective effects primarily by modulating growth factor receptor expression and downstream kinase signaling—particularly the VEGF axis driving new vessel formation and the FAK-paxillin pathway governing fibroblast adhesion and migration toward wound sites. TB-500 operates at a more fundamental cytoskeletal level by controlling G-actin availability, which directly governs whether cells can form the lamellipodia and filopodia required for directed migration toward repair signals. In research terms, BPC-157 may accelerate the chemical signaling environment that recruits and activates repair-competent cells, while TB-500 may enhance the physical capacity of those cells to migrate, proliferate, and deposit new matrix at injury sites. These non-overlapping mechanisms make the combination a rational subject for research investigating whether complementary tissue repair pathways can be engaged simultaneously in model systems.

Research Areas

What does BPC-157 + TB-500 Co-Formulation research examine regarding tendon and connective tissue?

Both BPC-157 and TB-500 have individually been studied in tendon and connective tissue repair research models. BPC-157 has been evaluated in Achilles tendon transection, quadriceps tendon rupture, and rotator cuff injury models, with research documenting accelerated tendon-to-bone healing, collagen fiber reorganization, and fibroblast infiltration into repair sites. TB-500 contributes to connective tissue research through its role in promoting tenocyte and fibroblast migration via actin dynamics modulation and its Ac-SDKP-mediated inhibition of TGF-β1-driven fibrosis, which can impede functional healing when excessive. Research combining both compounds in tendon and musculoskeletal repair contexts examines whether their complementary mechanisms—BPC-157’s vascularization promotion and TB-500’s cell migration facilitation—produce outcomes distinguishable from either compound alone in research injury systems.

How is the BPC-157 + TB-500 Co-Formulation studied in muscle research contexts?

Skeletal myofibrillar regeneration research has independently evaluated both BPC-157 and TB-500 in contusion, laceration, and ischemia-reperfusion muscle injury models. BPC-157 research in muscle injury models has reported effects on satellite cell activation, vascular supply restoration, and reduction of oxidative stress markers at injury sites. TB-500 research in muscle contexts has focused on its role in facilitating myoblast migration—a prerequisite for muscle fiber regeneration—through G-actin sequestration-driven cytoskeletal remodeling. The BPC-157 + TB-500 Co-Formulation combination is studied in muscle research to examine whether simultaneous engagement of growth factor signaling (BPC-157) and cytoskeletal dynamics (TB-500) produces measurable differences in muscle regeneration kinetics, fiber cross-sectional area restoration, and functional recovery endpoints in preclinical models.

What inflammation-related research applies to the BPC-157 + TB-500 Co-Formulation?

Both components of the BPC-157 + TB-500 Co-Formulation have documented anti-inflammatory properties in research contexts. BPC-157 has been studied for modulation of the nitric oxide pathway, with research suggesting effects on iNOS (inducible nitric oxide synthase) activity and consequent impact on inflammatory mediator profiles in injury models. TB-500’s N-terminal Ac-SDKP tetrapeptide inhibits prolyl oligopeptidase and has been reported to reduce macrophage-driven pro-inflammatory signaling while attenuating TGF-β1-mediated fibrotic responses in cardiac and connective tissue research models. Research combining both compounds examines whether these anti-inflammatory contributions are additive in reducing oxidative damage markers, inflammatory cell infiltration, and fibrotic deposition at injury sites in preclinical research systems.

Frequently Asked Questions

What is the BPC-157 + TB-500 Co-Formulation?

The BPC-157 + TB-500 Co-Formulation is a research peptide formulation combining BPC-157 (CAS 137525-51-0) and TB-500 (CAS 77591-33-4). BPC-157 is a 15-amino acid synthetic peptide derived from gastric juice protein BPC, studied for growth factor signaling modulation and angiogenesis in tissue repair research models. TB-500 is the 43-amino acid synthetic analogue of thymosin beta-4, studied for actin cytoskeletal dynamics regulation and cell migration facilitation. The combination is used in laboratory research examining complementary tissue repair mechanisms. Both compounds are for research use only.

What are the CAS numbers for the BPC-157 + TB-500 Co-Formulation components?

The BPC-157 + TB-500 Co-Formulation contains two compounds: BPC-157 with CAS number 137525-51-0 (molecular weight 1419.55 g/mol, 15-amino acid synthetic peptide) and TB-500 with CAS number 77591-33-4 (molecular weight 4963.4 g/mol, 43-amino acid synthetic thymosin-β4 analogue). Each compound is independently characterized and has its own published research base in preclinical tissue repair model systems.

How does BPC-157 differ from TB-500 mechanistically?

BPC-157 and TB-500 operate through distinct molecular mechanisms. BPC-157 (CAS 137525-51-0) modulates growth factor receptor activity—particularly VEGF signaling and FAK-paxillin pathway engagement—to promote vascularization, fibroblast activation, and cytoprotection. TB-500 (CAS 77591-33-4) acts as an actin G-monomer sequestering peptide via its LKKTETQ motif, regulating the dynamic balance between actin filament assembly and disassembly that governs cell motility. These non-overlapping mechanisms make them complementary tools for research investigating multi-pathway tissue repair biology.

What research models are used to study the BPC-157 + TB-500 Co-Formulation?

The BPC-157 + TB-500 Co-Formulation compounds have been studied individually and in combination in preclinical research models including tendon transection and repair models, skeletal muscle contusion and laceration models, wound healing assays measuring closure kinetics and granulation tissue formation, and ischemia-reperfusion injury models. Research using the combination formulation examines whether simultaneous engagement of BPC-157’s growth factor signaling modulation and TB-500’s cytoskeletal dynamics regulation produces measurably different outcomes compared with either compound studied independently in the same model systems.

What is the LKKTETQ motif in TB-500?

The LKKTETQ heptapeptide (Leu-Lys-Lys-Thr-Glu-Thr-Gln), corresponding to residues 17–23 of thymosin-β4 (TB-500), is the minimal actin-binding pharmacophore of the protein. This motif binds G-actin monomers with high affinity, sequestering unpolymerized actin and regulating the pool available for filament growth (F-actin). By controlling G-actin availability, the LKKTETQ-containing TB-500 modulates cell cytoskeletal dynamics, influencing cell shape, polarity, and the capacity for directed migration—all of which are relevant to research into tissue repair processes requiring coordinated cell movement toward wound sites.

What is the Ac-SDKP tetrapeptide associated with TB-500?

Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro) is the N-terminal tetrapeptide of thymosin-β4 (TB-500), released by prolyl oligopeptidase cleavage. Research has documented Ac-SDKP’s distinct anti-fibrotic and anti-inflammatory properties: it inhibits TGF-β1-driven myofibroblast differentiation and collagen deposition, suppresses macrophage pro-inflammatory activation, and may modulate bone marrow progenitor cell dynamics. Because Ac-SDKP activity is functionally distinct from the LKKTETQ actin-binding core, TB-500 research in the BPC-157 + TB-500 Co-Formulation context encompasses both cytoskeletal dynamics (LKKTETQ) and anti-fibrotic (Ac-SDKP) research applications.

What is the sequence of BPC-157?

BPC-157 has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), corresponding to a 15-residue fragment derived from the human gastric juice protein BPC. The peptide has CAS number 137525-51-0, molecular formula C₆₂H₉₈N₁₆O₂₂, and molecular weight of 1419.55 g/mol. It is a linear peptide with no disulfide bonds or unusual post-translational modifications, and has been studied across multiple organ systems in preclinical research with notable focus on gastrointestinal, musculoskeletal, and tendon repair model systems.

Is the BPC-157 + TB-500 Co-Formulation the same as a BPC-157 and TB-500 combination?

Yes. The BPC-157 + TB-500 Co-Formulation is the product designation for a research formulation containing BPC-157 (CAS 137525-51-0) and TB-500 (CAS 77591-33-4) as its two active research compounds. The GLOW Stack and KLOW Stack formulations are extensions that include additional peptide components: GHK-Cu is added in the GLOW Stack. The KLOW Stack is a separate four-peptide formulation containing BPC-157, GHK-Cu, KPV, and Ac-SDKP. The BPC-157 + TB-500 Co-Formulation is the core two-compound combination from which the GLOW Stack is built.

Published Research

The following peer-reviewed publications have examined BPC-157, TB-500 (thymosin beta-4), and related tissue repair research in preclinical contexts. These citations are provided for scientific reference and do not constitute endorsement of any application outside registered research programs.

• Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. PMID 21548867
• Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID 21148348
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair experimentally insulted tissues. Trends Mol Med. 2005;11(9):421–429. PMID 16099219
• Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144–2151. PMID 20181934
• Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. PMID 17108969
• Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2010;16(10):1224–1234. PMID 20030620

Research Use Only Disclaimer

The BPC-157 + TB-500 Co-Formulation (BPC-157, CAS 137525-51-0; TB-500, CAS 77591-33-4) is intended for laboratory research purposes by qualified professionals only. Not for human, animal, diagnostic, or therapeutic use. These compounds have not been evaluated by the FDA for clinical application, are not manufactured to pharmaceutical standards, and all applicable local, state, and federal regulations governing research compounds apply.